Scarica l'app Stockscreener
59.40
5.86%
3.29
Dopo l'orario di chiusura:
59.50
0.10
+0.17%
Precedente Chiudi:
$56.11
Aprire:
$56.04
Volume 24 ore:
2.80M
Relative Volume:
1.16
Capitalizzazione di mercato:
$10.99B
Reddito:
$2.69B
Utile/perdita netta:
$-214.04M
Rapporto P/E:
-37.46
EPS:
-1.5857
Flusso di cassa netto:
$98.43M
1 W Prestazione:
-3.02%
1M Prestazione:
+12.71%
6M Prestazione:
+35.00%
1 anno Prestazione:
-11.74%
Intervallo 1D:
$55.98
$59.70
Intervallo di 1 settimana:
$55.65
$62.15
Portata 52W:
$40.62
$79.62
Exact Sciences Corp Stock (EXAS) Company Profile
Nome
Exact Sciences Corp
Settore
Industria
Telefono
608-284-5700
Indirizzo
5505 ENDEAVOR LANE, MADISON, WI
Confronta EXAS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
59.40 | 10.99B | 2.69B | -214.04M | 98.43M | -1.17 |
|
TMO
Thermo Fisher Scientific Inc
|
524.05 | 200.45B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
228.55 | 165.08B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
134.51 | 38.36B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
197.27 | 35.80B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
412.26 | 33.76B | 3.84B | 866.24M | 792.60M | 10.37 |
Exact Sciences Corp Stock (EXAS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-08-28 | Iniziato | Wells Fargo | Overweight |
| 2024-06-27 | Iniziato | Scotiabank | Sector Outperform |
| 2024-06-03 | Ripresa | Jefferies | Buy |
| 2024-01-02 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-12-14 | Iniziato | Guggenheim | Buy |
| 2023-12-13 | Iniziato | Wolfe Research | Outperform |
| 2023-10-10 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | Iniziato | Bernstein | Outperform |
| 2023-08-02 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-05-10 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2023-05-05 | Iniziato | UBS | Neutral |
| 2023-03-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-02-10 | Downgrade | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | Downgrade | Craig Hallum | Buy → Hold |
| 2022-08-25 | Iniziato | Credit Suisse | Outperform |
| 2022-06-03 | Iniziato | Piper Sandler | Neutral |
| 2021-11-03 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | Reiterato | BTIG Research | Buy |
| 2021-07-29 | Reiterato | Canaccord Genuity | Buy |
| 2021-07-29 | Reiterato | Oppenheimer | Outperform |
| 2021-07-29 | Reiterato | Stifel | Buy |
| 2021-06-15 | Iniziato | Raymond James | Strong Buy |
| 2021-06-03 | Iniziato | Goldman | Buy |
| 2021-05-25 | Iniziato | Wells Fargo | Equal Weight |
| 2021-01-28 | Iniziato | Truist | Buy |
| 2020-10-29 | Downgrade | UBS | Buy → Neutral |
| 2020-10-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-10-08 | Ripresa | BTIG Research | Buy |
| 2020-04-02 | Iniziato | Evercore ISI | Outperform |
| 2020-01-10 | Ripresa | BTIG Research | Buy |
| 2020-01-07 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Dougherty & Company | Buy |
| 2019-11-15 | Iniziato | Stifel | Buy |
| 2019-10-17 | Reiterato | BofA/Merrill | Buy |
| 2019-10-01 | Ripresa | Craig Hallum | Buy |
| 2019-09-26 | Iniziato | Oppenheimer | Outperform |
| 2019-02-26 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-10-09 | Iniziato | UBS | Buy |
| 2018-09-05 | Ripresa | The Benchmark Company | Hold |
| 2018-08-13 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2018-01-29 | Iniziato | Goldman | Neutral |
| 2018-01-08 | Reiterato | The Benchmark Company | Buy |
| 2017-11-13 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | Downgrade | BTIG Research | Buy → Neutral |
Mostra tutto
Exact Sciences Corp Borsa (EXAS) Ultime notizie
Tidal Investments LLC Grows Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Toronto Dominion Bank - MarketBeat
Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Public Employees Retirement System of Ohio - MarketBeat
Exact Sciences (NASDAQ:EXAS) Price Target Lowered to $72.00 at Bank of America - MarketBeat
Exact Sciences Co. (NASDAQ:EXAS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Groupama Asset Managment Acquires Shares of 1,204,952 Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Corp reports results for the quarter ended in September 30Earnings Summary - XM
AAPA Awarded Grant from Exact Sciences to Improve Colorectal Cancer Screening Rates - Yahoo Finance
Pier Capital LLC Takes Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Soros Fund Management LLC Boosts Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Lil Jon Remixes Iconic ‘Get Low’ Hit To Promote Colon Cancer Screenings - Black Enterprise
Polar Asset Management Partners Inc. Acquires 45,800 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Co. (NASDAQ:EXAS) Shares Bought by Cerity Partners LLC - MarketBeat
Exact Sciences Corp (EXAS) Shares Up 4.18% on Dec 4 - GuruFocus.com
CFRA raises Exact Sciences to buy, target to $72 from $48 - Investing.com
Cinctive Capital Management LP Takes Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
The Manufacturers Life Insurance Company Acquires 35,927 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Beacon Investment Advisory Services Inc. Cuts Stock Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Stock Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences and Lil Jon Partner on Get Low #2 Campaign to Encourage Colon Cancer Screening - El Diario NY
Lil Jon partners with Exact Sciences to raise awareness for colorectal cancer screening - The Atlanta Voice
Exact Sciences and Lil Jon Partner on “Get Low #2” Campaign to Encourage Colon Cancer Screening - Mid Florida Newspapers
Exact Sciences Co. (NASDAQ:EXAS) Shares Acquired by BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp - MarketBeat
30,536 Shares in Exact Sciences Co. (NASDAQ:EXAS) Bought by Fred Alger Management LLC - MarketBeat
392,139 Shares in Exact Sciences Co. (NASDAQ:EXAS) Acquired by Erste Asset Management GmbH - MarketBeat
Bellevue Group AG Grows Stock Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Wasatch Advisors LP Reduces Stock Position in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by Braidwell LP - MarketBeat
Northwest & Ethical Investments L.P. Sells 36,242 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Spyglass Capital Management LLC Has $95.17 Million Holdings in Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Fisher Asset Management LLC Sells 36,302 Shares of Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
EXASExact Sciences Corp Latest Stock News & Market Updates - StockTitan
Soros Capital Management LLC Acquires Shares of 51,700 Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences stock lifted by TD Cowen, sees 10% revenue growth potential from CG+ - Investing.com Canada
Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology - GlobeNewswire Inc.
Why Is Exact Sciences Stock Trading Higher On Tuesday? (CORRECTED) - AOL
Exact Sciences stock outlook improves with Cologuard Plus launch and Medicare reimbursement - Investing.com
Exact Sciences stock rating maintained outperform as Medicare pricing boosts CG+ outlook - Investing.com
Exact Sciences stock up 10%, BTIG raises target after 16% price increase for Cologuard Plus - Investing.com
Exact Sciences shares keep outperform rating on Medicare fee schedule boost - Investing.com
S&P 500 Futures Climb in Premarket Trading; Woodward, Exact Sciences Lead - Barron's
Exact Sciences to Participate in December 2024 Investor Conferences - BioSpace
Exact Sciences to Participate in December Investor Conferences - Business Wire
Exact Sciences Advances Breast Cancer Care with the Oncotype DX® test and Genomic Profiling Research at SABCS 2024 - El Diario NY
Exact Sciences to present 10 abstracts on Precision Oncology portfolio at SABCS - TipRanks
Exact Sciences Advances Breast Cancer Care with the Oncotype DX - Business Wire
Exact Sciences to Present 10 Key Studies on Breast Cancer Test Effectiveness at SABCS - StockTitan
Exact Sciences Co. (NASDAQ:EXAS) Position Trimmed by Victory Capital Management Inc. - MarketBeat
B. Metzler seel. Sohn & Co. Holding AG Buys Shares of 32,194 Exact Sciences Co. (NASDAQ:EXAS) - MarketBeat
Exact Sciences data show multi-biomarker class approach improves MCED cancer detection - The Cancer Letter
Cathie Wood's ARK buys Tempus AI stock, sells Exact Sciences - Investing.com India
Exact Sciences Corp Azioni (EXAS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Exact Sciences Corp Azioni (EXAS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Baranick Brian | EVP, GM, Precision Oncology |
Oct 08 '24 |
Sale |
70.00 |
929 |
65,030 |
12,758 |
0.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):